BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:TREGZI (Orca-T) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of TREGZI (Orca-T)\, from ClinicalTrials.gov
  estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06551584-2968@assetmemo.bio
DTSTAMP:20261121T005813Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:TREGZI (Orca-T): Phase 1 readout est. (NCT06551584)
DESCRIPTION:TREGZI (Orca-T)\, phase 1\, Acute Myeloid Leukemia.\nStudy: Tri
 al for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic
  HCT\nEstimated primary completion: December 2026. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/orca-t#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06551584
URL:https://assetmemo.bio/drug/orca-t#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07216443-2968@assetmemo.bio
DTSTAMP:20261121T005813Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:TREGZI (Orca-T): Phase 2 readout est. (NCT07216443)
DESCRIPTION:TREGZI (Orca-T)\, phase 2\, Acute Myeloid Leukemia.\nStudy: Tri
 al of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning 
 in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome\nEstim
 ated primary completion: November 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/orca-t#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07216443
URL:https://assetmemo.bio/drug/orca-t#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
